anonymous
Guest
anonymous
Guest
Any company that would take over and sell Xiidra would deal with the same harsh reality that Novartis is dealing with. Boxed out of Part D plans by allergan and waiting for them to go generic. Whoever arranged the payoffs from allergen to keep the FDA from approving a generic is a genius. Hard to grow a product when 60% of your market isnt covered. doctors have been doing the access dance for almost 5 years and are sick of it. It doesnt matter how many fancy handouts we have. In a landscape where offices are losing so many employees so quickly who has the time or desire to train people to do all the PA and access work.
Although there’s some truth in this, you do know your goals have Part D removed, right? Are they audacious at times…yes. Unattainable? Nope. Are there issues with offices maintaining staff? Absolutely, and it plays a part. Bet your ass PA’s are still getting done for the drugs that they see value in.
They don’t see the value in Xiidra over restasis the majority of the time and that falls in the hands of sales. Half the force couldn’t message the MOA if their life depended on it. Quit being a prism dummy and go hammer your top prescribers in the market.
Weed out your cataract docs because you won’t win there and focus in on places you can move business. Live there. It’s really not that hard…you have one drug. ONE.
I come here for the laughs and to remind myself not to be a cry baby. Mission accomplished. Someone’s going to P club this year, no reason it can’t be anyone of us.
This gig really is so easy and Novartis is as good of a company as any in the industry. Ever wonder why people think pharma reps are a bunch of overpaid cheerleaders and frat boys? This shit right here…so much to wine about and such little regard for all of the blessings. Boo hoo. Seriously, grow up. Go do your job, have some pride and know that there’s an endless line of people who would gladly switch places with you.